贝特类药物治疗原发性胆汁性胆管炎的研究现状

卫晶; 武希润

doi:10.3969/j.issn.1001-5256.2020.02.046

贝特类药物治疗原发性胆汁性胆管炎的研究现状

DOI: 10.3969/j.issn.1001-5256.2020.02.046

卫晶,
武希润

山西医科大学第二医院消化内科

详细信息

中图分类号: R575.7
计量
- 文章访问数: 936
- HTML全文浏览量: 45
- PDF下载量: 247
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-19
- 出版日期: 2020-02-20

Current status of research on fibrates in treatment of primary biliary cholangitis

Wei Jing,
Wu XiRun

Department of Gastroenterology,The Second Hospital of Shanxi Medical University

摘要

摘要:
目前被美国食品药品监督管理局批准用于治疗原发性胆汁性胆管炎(PBC)的药物包括熊去氧胆酸和奥贝胆酸。对熊去氧胆酸应答不佳、不能耐受奥贝胆酸瘙痒副作用的患者亟需新的治疗药物。近年来大量基础实验和临床研究认为贝特类药物对PBC疗效显著。就贝特类药物治疗原发性胆汁性胆管炎的机制进展及临床应用作一综述。
- 原发性胆汁性胆管炎 /
- 纤维酸类 /
- 治疗学
Abstract:
At present,ursodeoxycholic acid( UDCA) and obeticholic acid( OCA) are approved by FDA for the treatment of primary biliary cholangitis( PBC). New drugs are urgently needed for the patients who have inadequate response to UDCA or cannot tolerate pruritus,a common side effect of OCA. In recent years,a large number of basic experiments and clinical studies have shown that fibrates have a good clinical effect in the treatment of PBC. This article reviews the advances in the mechanism and clinical application of fibrates in the treatment of PBC.
- primary biliary cholangitis /
- fibric acids /
- therapeutics

HTML全文

参考文献(42)

[1] CAREY EJ,ALI AH,LINDOR KD. Primary biliary cirrhosis[J].Lancet,2015,386(10003):1565-1575.

[2] BEUERS U,KREMER AE,BOLIER R,et al. Pruritus in cholestasis:Facts and fiction[J]. Hepatology,2014,60(1):399-407.

[3] HARMS MH,van BUUREN HR,CORPECHOT C,et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol,2019,71(2):357-365.

[4] SANTIAGO P,SCHEINBERG AR,LEVY C. Cholestatic liver diseases:New targets,new therapies[J]. Therap Adv Gastroenterol,2018,11:1756284818787400.

[5] KLIEWER SA,MANGELSDORF DJ. Bile acids as hormones:The FXR-FGF15/19 pathway[J]. Dig Dis,2015,33(3):327-331.

[6] NEVENS F,ANDREONE P,MAZZELLA G,et al. A placebocontrolled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med,2016,375(7):631-643.

[7] WILLSON TM,BROWN PJ,STERNBACH DD,et al. The PPARs:From orphan receptors to drug discovery[J]. J Med Chem,2000,43(4):527-550.

[8] HONDA A,IKEGAMI T,NAKAMUTA M,et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid[J]. Hepatology,2013,57(5):1931-1941.

[9] JONES D,BOUDES PF,SWAIN MG,et al. Seladelpar(MBX-8025),a selective PPAR-δagonist,in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid:A double-blind,randomised,placebo-controlled,phase2,proof-of-concept study[J]. Lancet Gastroenterol Hepatol,2017,2(10):716-726.

[10] XIE C,TAKAHASHI S,BROCKER CN,et al. Hepatocyte peroxisome proliferator-activated receptorαregulates bile acid synthesis and transport[J]. Biochim Biophys Acta Mol Cell Biol Lipids,2019,1864(10):1396-1411.

[11] GHONEM NS,ANANTHANARAYANAN M,SOROKA CJ,et al. Peroxisome proliferator-activated receptorαactivates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion[J]. Hepatology,2014,59(3):1030-1042.

[12] THOMAS M,BURK O,KLUMPP B,et al. Direct transcriptional regulation of human hepatic cytochrome P450 3A4(CYP3A4)by peroxisome proliferator-activated receptor alpha(PPARα)[J]. Mol Pharmacol,2013,83(3):709-718.

[13] BARBIER O,DURAN-SANDOVAL D,PINEDA-TORRA I,et al. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme[J]. J Biol Chem,2003,278(35):32852-32860.

[14] SENEKEO-EFFENBERGER K,CHEN S,BRACE-SINNOKRAK E,et al. Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid(WY-14643)and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation[J].Drug Metab Dispos,2007,35(3):419-427.

[15] FANG HL,STROM SC,CAI H,et al. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor[J]. Mol Pharmacol,2005,67(4):1257-1267.

[16] TOYAMA T,NAKAMURA H,HARANO Y,et al. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats[J]. Biochem Biophys Res Commun,2004,324(2):697-704.

[17] WEI Z,ZHAO D,ZHANG Y,et al. Rosiglitazone ameliorates bile duct ligation-induced liver fibrosis by down-regulating NF-κB-TNF-αsignaling pathway in a PPARγ-dependent manner[J]. Biochem Biophys Res Commun,2019,519(4):854-860.

[18] HAUGHTON EL,TUCKER SJ,MAREK CJ,et al. Pregnane X receptor activators inhibit human hepatic stel ate cell transdifferentiation in vitro[J]. Gastroenterology,2006,131(1):194-209.

[19] IWAISAKO K,HAIMERL M,PAIK YH,et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptorδagonist[J]. Proc Natl Acad Sci U S A,2012,109(21):e1369-e1376.

[20] RODRÍGUEZ-VILARRUPLA A,LAVINA B,GARCÍA-CALDEROH,et al. PPARαactivation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats[J]. J Hepatol,2012,56(5):1033-1039.

[21] MORAES LA,PIQUERAS L,BISHOP-BAILEY D. Peroxisome proliferator-activated receptors and inflammation[J]. Pharmacol Ther,2006,110(3):371-385.

[22] SHIMODA S,HISAMOTO S,HARADA K,et al. Natural killer cells regulate T cell immune responses in primary biliary cirrhosis[J]. Hepatology,2015,62(6):1817-1827.

[23] CHEN QB,PENG AP,LI CC,et al. Suppressive effects of bezafibrate on proliferation and cytokine production by CD4+T cells from patients with primary biliary cirrhosis[J]. Chin J Immunol,2014,30(10):1388-1392.(in Chinese)陈曲波，彭桉平，黎翠翠，等．苯扎贝特对原发性胆汁性肝硬化患者外周血CD4+T细胞的抑制作用研究[J]．中国免疫学杂志，2014,30(10):1388-1392.

[24] DELERIVE P,GERVOIS P,FRUCHART JC,et al. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators[J]. J Biol Chem,2000,275(47):36703-36707.

[25] KORBECKI J,BOBINSKI R,DUTKA M. Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors[J]. Inflamm Res,2019,68(6):443-458.

[26] WALLACE K,COWIE DE,KONSTANTINOU DK,et al. The PXR is a drug target for chronic inflammatory liver disease[J].J Steroid Biochem Mol Biol,2010,120(2-3):137-148.

[27] ZHANG N,CHU ES,ZHANG J,et al. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway[J]. Oncotarget,2014,5(18):8330-8340.

[28] JIAO HL,ZHAO BL. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms[J]. Toxicol Appl Pharmacol,2002,185(3):172-179.

[29] YAMASAKI D,KAWABE N,NAKAMURA H,et al. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms[J]. Eur J Cell Biol,2011,90(8):657-664.

[30] HAYS T,RUSYN I,BURNS AM,et al. Role of peroxisome proliferator-activated receptor-alpha(PPARalpha)in bezafibrate-induced hepatocarcinogenesis and cholestasis[J].Carcinogenesis,2005,26(1):219-227.

[31] PYPER SR,VISWAKARMA N,YU S,et al. PPARalpha:Energy combustion,hypolipidemia,inflammation and cancer[J].Nucl Recept Signal,2010,8:e002.

[32] LIAN X,WANG G,ZHOU H,et al. Anticancer properties of fenofibrate:A repurposing use[J]. J Cancer,2018,9(9):1527-1537.

[33] MA TL. Efficacy and safety evaluation of fenofibrate combined with rosuvastatin in the treatment of high-risk mixed hyperlipidemia[J]. J Changchun Univ Chin Med,2019,35(5):946-949.(in Chinese)马腾龙．非诺贝特联合瑞舒伐他汀治疗高危混合性高脂血症的疗效及安全性评价[J]．长春中医药大学学报，2019,35(5):946-949.

[34] DAY AP,FEHER MD,CHOPRA R,et al. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities[J]. Metabolism,1993,42(7):839-842.

[35] CORPECHOT C,CHAZOUILLERES O,ROUSSEAU A,et al.A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J]. N Engl J Med,2018,378(23):2171-2181.

[36] GRIGORIAN AY,MARDINI HE,CORPECHOT C,et al. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis:A meta-analysis[J]. Clin Res Hepatol Gastroenterol,2015,39(3):296-306.

[37] HONDA A,TANAKA A,KANEKO T,et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis[J]. Hepatology,2019,70(6):2035-2046.

[38] WANG L,SUN KS,HAN ZY,et al. Clinical effect of fenofibrate combined with ursodeoxycholic acid in treatment of primary biliary cholangitis patients with poor response to ursodeoxycholic acid alone[J]. J Clin Hepatol,2018,34(11):2368-2372.(in Chinese)王璐，孙可帅，韩者艺，等．非诺贝特联合熊去氧胆酸治疗单用熊去氧胆酸应答不佳的原发性胆汁性胆管炎患者的效果评价[J]．临床肝胆病杂志，2018,34(11):2368-2372.

[39] DOHMEN K,TANAKA H,HARUNO M,et al. Biochemical and histological effectiveness of long-term use of fenofibrate for asymptomatic primary biliary cholangitis[J]. J Gastroenterol Hepatol Res,2016,5(4):2125-2131.

[40] AGRAWAL R,MAJEED M,ATTAR BM,et al. Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis:A meta-analysis of randomized controlled trials[J]. Ann Gastroenterol,2019,32(5):489-497.

[41] DUAN W,OU X,WANG X,et al. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA[J]. Rev Esp Enferm Dig,2018,110(9):557-563.

[42] DOHMEN K,TANAKA H,HARUNO M. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis[J]. Fukuoka Igaku Zasshi,2013,104(10):350-361.

施引文献

资源附件(0)

访问统计